Metallopolymer and Antibiotic Bioconjugates against Multidrug Resistant Bacteria
Metallopolymer and Antibiotic Bioconjugates against Multidrug Resistant Bacteria
批准号:
9001064
负责人:
Chuanbing Tang
金额:
$36.16万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-11-01 至 2019-10-31
关键词:
AcylationAddressAdsorptionAdvanced DevelopmentAmino AcidsAmoxicillinAmoxicillin-Potassium Clavulanate CombinationAmpicillinAnionsAntibiotic TherapyAntibioticsBacteriaBacterial InfectionsBacterial TypingCefazolinCell Culture TechniquesCell WallCell membraneCell surfaceCellsCessation of lifeChargeClinicalCommunicable DiseasesComplexCytolysisDefense MechanismsDevelopmentDrug resistanceEnzymesEukaryotic CellExcretory functionExhibitsFrequenciesGoalsGram-Positive Bacterial InfectionsHealth Care CostsHealthcareHumanHydrolysisIn VitroInfectionIonsLactamaseLeadMammalian CellMetabolismMetalsMethicillinMethodsMicrobiologyModern MedicineMonobactamsMorbidity - disease rateMulti-Drug ResistanceMusNatural regenerationNosocomial InfectionsPathway interactionsPatientsPenicillin GPenicillin ResistancePolymer ChemistryPolymersPredispositionProductionRecurrenceResearchResidual stateResistance developmentRoleStructureSuperbugSystemTechniquesTestingTissuesToxic effectVancomycinWorkX-Ray Crystallographyabsorptionantimicrobialantimicrobial drugantimicrobial peptidebacterial resistancebasebeta-Lactamasebeta-Lactamscarboxylatecytotoxicdeacylationdesigndisabilityfightingin vivoinnovationkillingsmetal poisoningmethicillin resistant Staphylococcus aureusnovelpathogenpreventpublic health relevancescaffoldstructural biologysuccesssystemic toxicity
中文摘要
描述:细菌感染是一个重要的和正在出现的全球医疗保健问题。Β-Lactam抗生素是现代医学最重要的发展之一,它拯救了数以百万计的生命,并继续作为治疗细菌感染的主要疗法。高活性的四元β-内酰胺环是决定这类抗生素疗效的关键结构。不幸的是,细菌正在迅速对一种或多种最常用的抗生素产生抗药性。Β-内酰胺酶的产生和排泄是几种耐药细菌的主要防御机制。例如,近30%的医院获得性感染被鉴定为耐甲氧西林金黄色葡萄球菌,对青霉素、甲氧西林和许多其他β-内酰胺类抗生素具有耐药性,导致患者面临严重的感染问题。目前,万古霉素和阿莫西林/克拉维酸是治疗革兰氏阳性细菌感染最常用的抗生素。虽然这些抗生素是其类别中最强的,但频繁使用已导致它们的敏感性降低。高效的抗生素和/或抗菌剂需求量很大,但在对抗细菌耐药性方面成效有限。我们发现了一类带电金属聚合物,它通过有效地裂解细菌细胞和有效地解除β-内酰胺酶的活性而显示出抗多药耐药细菌的协同作用。各种传统的β-内酰胺类抗生素,包括青霉素-G、阿莫西林、氨苄西林和头孢唑林,通过以下途径防止β-内酰胺酶的水解
它们的羧酸盐阴离子和阳离子金属聚合物之间形成独特的离子对。该项目至少涉及三项创新:(1)我们的方法通过保护和恢复抗生素有效防止细菌耐药性;(2)更重要的是,我们的金属聚合物平台通过解除β-内酰胺酶的武装并破坏细胞膜,消除了细菌耐药性复发的可能性;(3)这些金属聚合物对哺乳动物细胞无细胞毒性或最低限度地降低了细胞毒性。我们的研究和发现可能为设计大分子支架提供一条新的途径,以再生传统抗生素的活力,从而杀死耐多药细菌和超级细菌。
英文摘要
DESCRIPTION: Bacterial Infections are an important and emerging global healthcare issue. Β-Lactam antibiotics, one of the most important developments in modern medicine, have saved millions of lives and continue to serve as the major therapy to treat bacterial infections. The highly reactive four- membered β-lactam ring is the key structure for dictating efficacy of this class of antibiotics. Unfortunately, bacteria are rapidly developing resistance to one or more of the most frequently used antibiotics. Β-Lactamase production and excretion is a major defense mechanism employed by several drug-resistant bacterial pathogens. For example, nearly 30% of hospital- acquired infections are identified as methicillin-resistant Staphylococcus aureus (MRSA) strains that are resistant to penicillin, methicillin and many other β-lactam antibiotics, leading to serious infection problems for patients. Currently, vancomycin and amoxicillin/clavulanic acid are among the most commonly used antibiotics for the treatment of Gram-positive bacterial infections. Although these antibiotics are among the strongest of their classes, the high frequency use has resulted in their decreased susceptibility. Efficient antibiotics and/or antimicrobial agents are in high demand, but have limited success in fighting bacterial resistance. We discover a class of charged metallopolymers that exhibits synergistic effects against multidrug resistant bacteria by effectively lysing bacterial cells and efficiently disarming activity of β-lactamases. Various conventional β-lactam antibiotics, including penicillin-G, amoxicillin, ampicillin and cefazolin, are protected from β-lactamase hydrolysis via
the formation of unique ion-pairs between their carboxylate anions and cationic metallopolymers. There are at least three innovations involved in this project: (1) our approaches effectively prevent bacterial resistance by protecting and reinstating antibiotics; (2) more importantly our metallopolymer platforms eliminate the possibility of recurrence of bacterial resistance via disarming β- lactamases and disrupting cell membranes; (3) these metallopolymers are non- or minimally cytotoxic for mammalian cells. Our research and discoveries could provide a new pathway to designing macromolecular scaffolds to regenerate vitality of conventional antibiotics to kill multidrug resistant bacteria and superbugs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Control of Facial Amphiphilicity to Tune Macromolecular Interactions with Bacteria
-
批准号:10062831
-
项目类别:
-
资助金额:$36.52万
-
财政年份:2019
-
负责人:Chuanbing Tang
-
依托单位:
Control of Facial Amphiphilicity to Tune Macromolecular Interactions with Bacteria
-
批准号:9886334
-
项目类别:
-
资助金额:$36.91万
-
财政年份:2019
-
负责人:Chuanbing Tang
-
依托单位:
Control of Facial Amphiphilicity to Tune Macromolecular Interactions with Bacteria
-
批准号:10304183
-
项目类别:
-
资助金额:$36.52万
-
财政年份:2019
-
负责人:Chuanbing Tang
-
依托单位:
Control of Facial Amphiphilicity to Tune Macromolecular Interactions with Bacteria
-
批准号:10530614
-
项目类别:
-
资助金额:$36.52万
-
财政年份:2019
-
负责人:Chuanbing Tang
-
依托单位:
Metallopolymer and Antibiotic Bioconjugates against Multidrug Resistant Bacteria
-
批准号:9173018
-
项目类别:
-
资助金额:$36.16万
-
财政年份:2015
-
负责人:Chuanbing Tang
-
依托单位:
海外基金